Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 16:07 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Reports Third Quarter 2025 Results

Castle Biosciences, Inc. (Nasdaq: CSTL) today announced its financial results for the third quarter and nine months ended Sept. 30, 2025.
October 26, 2025 15:05 ET | Source: Castle Biosciences, Inc.

New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett’s Esophagus

Castle announced new data on its TissueCypher® Barrett’s Esophagus test being presented at ACG 2025.
October 24, 2025 04:05 ET | Source: Castle Biosciences, Inc.

New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

Castle is presenting data on DecisionDx®-Melanoma and its pipeline atopic dermatitis (AD) test at the 25th Annual Fall Clinical Dermatology Conference.
September 17, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Named One of Newsweek’s America’s Greatest Companies 2025

Castle Biosciences has been included in the inaugural 2025 America’s Greatest Companies list, published by Newsweek.
September 09, 2025 07:00 ET | Source: Castle Biosciences, Inc.

New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions

Castle will share new data on its TissueCypher Barrett’s Esophagus test via a podium presentation on Sept. 13 at the AFS 2025 Annual Meeting.
August 25, 2025 07:00 ET | Source: Castle Biosciences, Inc.

New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma

Castle announced the publication of two new studies related to its DecisionDx-SCC test for patients with high-risk cutaneous squamous cell carcinoma.
August 04, 2025 16:05 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Reports Second Quarter 2025 Results

Delivered Q2 2025 revenue of $86 million Q2 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 33% over Q2 2024 Raising full-year 2025 revenue...
July 25, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal

Castle announced that its chief executive officer Derek Maetzold has been named a 2025 Most Admired CEO by the Houston Business Journal.
July 23, 2025 07:00 ET | Source: Castle Biosciences, Inc.

FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test

Castle announced that its DecisionDx®-Melanoma test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).
July 17, 2025 07:00 ET | Source: Castle Biosciences, Inc.

Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture

Castle Biosciences announced that it has earned multiple awards through the 2025 Top Workplaces program recognizing its strong company culture.